Business Wire·Aug 11, 2026, 4:01 PM ET

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Biologics Inc. announced the commencement of an underwritten public offering of $200.0 million in common shares & pre-funded warrants to purchase common shares.
All securities are being offered by AbCellera & the offering is subject to market conditions with no assurance regarding completion, size, or terms.
Net proceeds will fund research, development, clinical advancement of the internal pipeline (including lead program ABCL635), working capital, & general corporate purposes.
Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, & BMO Capital Markets are acting as joint book-running managers.
The offering is conducted pursuant to a shelf registration statement on Form S-3ASR filed with the SEC on February 27, 2025.
No securities are being offered or sold in Canada or to Canadian residents.
AbCellera is a clinical-stage biotechnology company focused on antibody-based medicines in endocrinology, women's health, immunology, oncology, & other areas.